ACPU
JAZZ icon

Arrowgrass Capital Partners (US)’s Jazz Pharmaceuticals JAZZ Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-10,000
Closed -$1.35M – 305
2017
Q4 		$1.35M Buy
+10,000
New +$1.39M 0.01% 416

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s JAZZ Position: Q2 2018 in Review

Arrowgrass Capital Partners (US) sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2018, closing a stake of 37,873 shares — an estimated $5.72M sold.

Arrowgrass Capital Partners (US) first reported a position in JAZZ in Q4 2014 and held it in 13 quarters. The position peaked at $21.6M in Q3 2017. 376 funds tracked by Wall St. Rank hold JAZZ as of Q2 2018.

  • Arrowgrass Capital Partners (US) reported no remaining Jazz Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 37,873 Jazz Pharmaceuticals shares in Q2 2018, an estimated $5.72M.
  • Arrowgrass Capital Partners (US) first reported a position in Jazz Pharmaceuticals in Q4 2014 and held it in 13 quarters.
  • Arrowgrass Capital Partners (US)'s Jazz Pharmaceuticals position peaked at $21.6M in Q3 2017.
  • 376 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2018.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q2 2018, filed 14 Aug 2018.